FDA has their eye on vaccine adjuvants: What are they seeing? Register for March 30 FDA Grand Rounds and Find Out

The March 30 FDA Grand Rounds webcast presents the latest in FDA vaccine research

Register here for CE Credit

Vaccine adjuvants: New ways to evaluate their safety and effectiveness

Thursday, March 30, 2017
12:00 p.m. -1:00 p.m. EST

Presented by 

Dr. Hana Golding
Research Chemist
FDA's Center for Biologics
Evaluation and Research

 5 Things You’ll Take Away From This FDA Scientist:

1. What are adjuvants and how do they work?
2. How do adjuvants improve the quality of immune responses?
3. Can adjuvanted vaccines elicit broader (cross-reactive) immunity against pandemic influenza?
4. Are there safety concerns?
5. Can in vitro assays complement pre-clinical studies in animals?

About the Presentation

Dr. Golding’s laboratory has developed new cellular assays to evaluate the safety of new adjuvants using human cells. Her team has also developed new molecular tools to analyze the antibody responses elicited by adjuvanted vaccines and to compare them with responses of unadjuvanted vaccine recipients, as well as with patients who have recovered from the infection.
The insights gained from her group research could improve the evaluation of future adjuvanted vaccines against diverse disease-causing microorganisms and identify biomarkers of safety and efficacy.